Chemomab Therapeutics Ltd. — Director's Dealing 2021

Mar 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Chemomab Therapeutics Ltd. (CMMB)
CIK: 0001534248
Period of Report: 2021-03-16

Reporting Person: OrbiMed Israel GP Ltd. (10% Owner)
Reporting Person: OrbiMed Israel BioFund GP Limited Partnership (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-16	American Depository Shares	A	288170	$17.35	Acquired	2578174	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-16	Warrants (Right to Buy)	$17.35	A	28817	Acquired	2026-03-16	American Depository Shares (28817)	Indirect

Footnotes

F1: Each ADS represents twenty (20) Ordinary Shares of the Issuer. These ADSs were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.

F2: These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

F3: This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4: The warrants are held of record by OIP and are immediately exercisable.